- Home
- AUTL vs OLMA Comparison
AUTL vs OLMA Comparison
Compare AUTL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- OLMA
- Stock Information
- Founded
- AUTL 2014
- OLMA 2006
- Country
- AUTL United Kingdom
- OLMA United States
- Employees
- AUTL N/A
- OLMA N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- OLMA Health Care
- Exchange
- AUTL Nasdaq
- OLMA Nasdaq
- Market Cap
- AUTL 360.6M
- OLMA 289.0M
- IPO Year
- AUTL 2018
- OLMA 2020
- Fundamental
- Price
- AUTL $1.51
- OLMA $5.01
- Analyst Decision
- AUTL Strong Buy
- OLMA Strong Buy
- Analyst Count
- AUTL 5
- OLMA 3
- Target Price
- AUTL $9.32
- OLMA $27.67
- AVG Volume (30 Days)
- AUTL 2.0M
- OLMA 1.0M
- Earning Date
- AUTL 05-08-2025
- OLMA 05-07-2025
- Dividend Yield
- AUTL N/A
- OLMA N/A
- EPS Growth
- AUTL N/A
- OLMA N/A
- EPS
- AUTL N/A
- OLMA N/A
- Revenue
- AUTL $10,120,000.00
- OLMA N/A
- Revenue This Year
- AUTL $277.74
- OLMA N/A
- Revenue Next Year
- AUTL $221.89
- OLMA N/A
- P/E Ratio
- AUTL N/A
- OLMA N/A
- Revenue Growth
- AUTL 496.00
- OLMA N/A
- 52 Week Low
- AUTL $1.11
- OLMA $2.86
- 52 Week High
- AUTL $5.00
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- AUTL 49.38
- OLMA 70.01
- Support Level
- AUTL $1.32
- OLMA $2.96
- Resistance Level
- AUTL $1.45
- OLMA $3.41
- Average True Range (ATR)
- AUTL 0.16
- OLMA 0.34
- MACD
- AUTL 0.04
- OLMA 0.22
- Stochastic Oscillator
- AUTL 65.85
- OLMA 90.34
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.